Table 3 Baseline characteristics according to prior biologic therapy use
From: Real-life experience with benralizumab during 6 months
Variables | Biologic treatment-naïve patients (n = 20) | Patients with prior biologic therapy (n = 22) | p |
|---|---|---|---|
Age, years; md (IR) | 58 (20.75) | 52 (14.75) | 0.089 |
Women, n (%) | 16 (80) | 17 (77.3) | 1 |
BMI, md (IR) | 28 (6.75) | 27.5 (8.5) | 0.980 |
Age at diagnosis, years; md (IR) | 30 (24) | 22.5 (14) | 0.079 |
Atopy, n (%) | 2 (10) | 12 (54.5) | 0.01 |
Corticosteroid-dependent, n (%) | 7 (35) | 10 (46) | 0.708 |
Nasal polyps, n (%) | 3 (15) | 9 (41) | 0.130 |
AERD, n (%) | 0 (0) | 6 (27) | 0.022 |
ACT, md (IR) | 14 (6) | 13.5 (6) | 0.430 |
ED visits in the previous year; md (IR) | 5 (2) | 3 (6) | 0.325 |
Cycles of OCS in the previous year; md (IR) | 7 (2) | 5 (7) | 0.155 |
Oral prednisone (or equivalent) dose, mg/day; md (IR) | 20 (15) | 17.5 (20) | 0.579 |
Post-BD FEV1, mL; md (IR) | 1420 (835) | 1445 (913) | 0.980 |
Post-BD FEV1, %; md (IR) | 65 (13) | 66.5 (16) | 0.404 |
FeNO, ppb; md (IR) | 66 (32) | 60 (60) | 0.351 |
Blood eosinophil count, cells/ÎĽL; md (IR) | 755 (315) | 660 (205) | 0.177 |
IgE, IU/mL; md (IR) | 43.5 (40) | 216 (288) | < 0.001 |